All News

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Researchers addressed the association between semaglutide use and the risk of nonarteritic anterior ischemic optic neuropathy.

“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Catch up on important continuous glucose monitoring (CGM) news from the month of June.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Through a test-and-treat approach, patients who test positive for HCV RNA with the Xpert HCV test and GeneXpert Xpress System can be connected to care as soon as the same health care visit.

Drug Topics has been on site at McKesson ideaShare this week! Check out this podcast to hear a few of the things we've experienced and what we've learned so far.

Check out these important FDA updates from the month of June 2024.

At McKesson ideaShare 2024, Andrea Sikora discussed artificial intelligence and how it has gradually been integrated into health care systems.

Test your pharmacy news knowledge with our weekly quiz.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

The first-in-class selective dual PDE3 and PDE4 inhibitor from Verona Pharma is the first inhaled product with a novel mechanism of action approved to treat COPD in over 20 years.

Check out this list of our top 10 most read stories from June 2024.

A study found that cannabis use increased the risk of hospitalization and intensive care unit admission following a COVID-19 diagnosis.

Check out these featured Drug Topics expert interviews from June 2024.

Drug Topics has been on site at McKesson ideaShare this week. Check out this podcast to hear a few of the exciting happenings at this year’s meeting.

The can’t-miss event on July 13 features speakers and CE sessions focused on streamlining pharmacy finances and services.

A study found that having a high level of melanoma knowledge was significantly correlated with having risk factors for the disease, such as skin ultraviolet radiation vulnerability and lighter hair color.

Check out these top featured stories from Drug Topics in June 2024.

In case you missed it, this week we had news about migraine myths, the ongoing bird flu outbreak, improving vaccine hesitancy, and more.

The strongest independent predictors of becoming adherent to dermatology follow-up included younger age and prior outpatient visits.

Check out important updates from the FDA for the week of June 17.